5-Bromo-4-fluoro-1-methylindazole; 1H-Indazole, 5-bromo-4-fluoro-1-methyl-; 5-Bromo-4-fluoro-1-m; Orforglipron Intermediates
CAS: 1784678-61-0
Chemical Formula: C₈H₆BrFN₂
Molecular Weight: 229.05
Availability: R&D; Commercialization
⬤ CAS No.1784678-61-0
⬤ Our Packaging type：
20kg barrel；5kg barrel；1kg bag；500g bag ; Customized Packaging
| Product Name | 5-bromo-4-fluoro-1-methyl-1H-indazole |
| CAS.No | 1784678-61-0 |
| Molecular Formula | C₈H₆BrFN₂ |
| Molecular Weight | 229.05 |
| Related Categories | Orforglipron Intermediates |
| Appearance | solid |
| Boiling Point | 293.4±20.0 °C(Predicted) |
| Density | 1.70±0.1 g/cm³ (Predicted) |
| Acidity coefficient（pKa） | -0.38±0.30 (Predicted) |
| Flash Point | 131.3±21.8 °C (Predicted) |
| Chemical Structure | The compound is a halogenated indazole derivative, and its structural characteristics are that the benzene ring is fused with the pyrazole ring, the bromine and fluorine atoms are connected at the 5-position and 4-position respectively, and the methyl group is connected at the 1-position. |
| Dangerous goods signs | GHS07 Warning |
| Hazard Labeling | H302 (Note: Harmful if swallowed) |
| Application | 5-Bromo-4-fluoro-1-methyl-1H-indazole is an important intermediate in the synthesis of potential drug candidates in various therapeutic areas, including cancer, neurodegenerative diseases, and infectious diseases. |
Reliable Global Partner
“Tianming Pharmaceutical has redefined reliability for us. Their ability to deliver high-potency APIs and intermediates under tight deadlines—is unmatched. The team’s transparency in documentation and proactive updates make them a stress-free partner. A true backbone for our operations!”
March 18, 2024
Outstanding Technical Guidance
“Few suppliers align so perfectly with EU GMP requirements. Tianming’s commitment to audit-ready quality systems, batch traceability, and purity consistency has streamlined our production processes. Their diligence eliminates regulatory risks—a rare advantage in today’s market.”
February 15, 2024
Beyond Supplier, A Solutions Partner
“Tianming’s technical team doesn’t just deliver materials—they solve problems. When we faced stability challenges with a niche compound, their scientists proposed a tailored purity adjustment that saved our project timeline. Their agility transforms obstacles into opportunities.”
June 15, 2024
Strategic Growth Ally
“Over 5+ years, Tianming has consistently adapted to our evolving needs—whether scaling volumes or supporting custom synthesis projects. Their ethical pricing models and long-term vision make them more than a vendor; they’re integral to our competitive edge.”
April 27, 2024
Regulatory differences between API and intermediate manufacturing under ICH Q7, FDA, EMA, and NMPA. GMP boundaries, DMF filing, starting material justification.
Finerenone drug class: third‑generation non‑steroidal MRA. Compare selectivity, potency, half‑life, and safety vs spironolactone/eplerenone. FDA‑approved for CKD+T2D and HF with LVEF ≥40%.
Finerenone mechanism of action: a non‑steroidal mineralocorticoid receptor antagonist with high MR selectivity, balanced cardiorenal distribution, no active metabolites, and lower hyperkalemia risk vs steroidal MRAs.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.
